Graham Capital Management, L.P. Supernus Pharmaceuticals, Inc. Transaction History
Graham Capital Management, L.P.
- $4.38 Billion
- Q1 2025
A detailed history of Graham Capital Management, L.P. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 8,215 shares of SUPN stock, worth $273,313. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,215
Previous 6,908
18.92%
Holding current value
$273,313
Previous $249,000
8.03%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$346 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$205 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$173 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$96.6 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$89.8 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.78B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...